OriGene Technologies, Inc.
Left ProductsProducts divider ServicesServices divider technologyTechnology divider researchResearch divider TechsupportTechSupport divider AboutAbout Right
Home Antibody All anti-MAP3K8 antibodies

Anti-MAP3K8 GAT Antibody Polyclonal

Generated by Genomic Immunization


Specifications Citations Customer Reviews Product Documents
SKU Description Amount Price Availability*  
TA590197 Rabbit Polyclonal MAP3K8 Antibody 100ug $325 In Stock
Add to Shopping Cart
Write Review & Get Rewarded

Write a review and get rewarded!

Review this antibody and earn an OriGene coupon or Amazon giftcard

Follow these easy steps to reward yourself:

  1. Sign in to your account, or register for a new account;
  2. Write a review;
  3. Receive a coupon or giftcard once your review is accepted.

Click the button to start writing a review

OriGene Data

ImmunogenDNA immunization. This antibody is specific for the Middle Region of the target protein.
Clone NamePolyclonal IsotypeIgG
Species ReactivityHuman Concentration0.89mg/ml
Guaranteed Application *ELISA Suggested Dilutions WB 1:20000,ELISA 1:100-1:2000
Buffer20 mM Potassium Phosphate, 150 mM Sodium Chloride, pH 7.0
Purification The fragment used for DNA immunization was expressed in E.coli and the purified protein fragment was used for affinity purification of the antibody.
Note This antibody was generated by SDIX's Genomic Antibody Technology ® (GAT). Learn about GAT

Reference Data

Target NameHomo sapiens mitogen-activated protein kinase kinase kinase 8 (MAP3K8), transcript variant 1
Alternative NameAURA2; c-COT; COT; EST; ESTF; MEKK8; Tpl-2; TPL2
Database LinkNP_005195
Entrez Gene 1326 Human
FunctionTPL-2, a MEK kinase is essential for TLR4 activation of the ERK mitogen-activated protein kinase cascade in lipopolysaccharide (LPS)-stimulated macrophages. Interaction with p105 is required to maintain TPL-2 metabolic stability and also negatively regulates TPL-2 MEK kinase activity (1). The NF-kappaB1 gene encodes a larger precursor protein, p105, from which p50 is produced constitutively by proteasome-mediated removal of the p105 carboxy terminus. TPL-2 , which is homologous to MAP-kinase-kinase kinases in its catalytic domain, forms a complex with the carboxy terminus of p105. TPL-2 was originally identified, in a carboxy-terminal-deleted form, as an oncoprotein in rats and is more than 90% identical to the human oncoprotein COT. Expression of TPL-2 results in phosphorylation and increased degradation of p105 while maintaining p50 production. This releases associated Rel subunits or p50-Rel heterodimers to generate active nuclear NF-kappaB. Furthermore, kinase-inactive TPL-2 blocks the degradation of p105 induced by tumor-necrosis factor-alpha. TPL-2 is therefore a component of a new signaling pathway that controls proteolysis of NF-kappaB1 p105 (2).
Related PathwayProtein KinaseDruggable Genome MAPK signaling pathwayToll-like receptor signaling pathwayT cell receptor signaling pathway

* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.

ELISA: MAP3K8 Antibody


Inc 5000 Healthcare Company
All Products by: Title | Price | Category | Popularity | Best Sellers Topselling Products by: Title | Price | Category | Popularity | Favorites
Popular Categories: Popularity | Our Choices | All-Round Favorites | Title Topselling Categories: Popularity | Our Choices | All-Round Favorites | Title

Notice to Non-US Customers

ExclaimationWeb price and delivery time are for direct sales only.

Non-US customers are encouraged to contact our dedicated distributor network for quotes and streamlined ordering/delivery support.